Search

Your search keyword '"van den Ham, Hendrika A."' showing total 247 results
Start Over Author "van den Ham, Hendrika A."
247 results on '"van den Ham, Hendrika A."'

1. Navigating the path towards successful implementation of the EU HTA Regulation: key takeaways from the 2023 Spring Convention of the European Access Academy

Author

Brinkhuis, Francine, Julian, Elaine, van den Ham, Hendrika, Gianfrate, Fabrizio, Strammiello, Valentina, Berntgen, Michael, Pavlovic, Mira, Mol, Peter, Wasem, Jürgen, Van Dyck, Walter, Cardone, Antonella, Dierks, Christian, Schiel, Anja, Bernardini, Renato, Solà-Morales, Oriol, Ruof, Jörg, and Goettsch, Wim

Published
2024
Full Text
View/download PDF

8. Missing data on accessibility of children's medicines/Manque de donnees sur l'accessibilite aux medicaments pediatriques/Faltan datos sobre la accesibilidad de los medicamentos pediatricos

Author

Joosse, Iris R., Mantel-Teeuwisse, Aukje K., Wirtz, Veronika J., Suleman, Fatima, and van den Ham, Hendrika A.

Subjects
Sustainable development -- Surveys, Children -- Diseases, Physical instruments -- Surveys, Drugs -- Surveys, Data entry -- Surveys, Health, Health Action International -- Surveys, World Health Organization -- Surveys
Abstract

Child-appropriate medicines are essential for the safe and effective treatment of children, yet we have observed a large gap in the data required to adequately monitor access to these medicines. We have examined data on the availability and pricing of child-appropriate medicines across 50 surveys. Child-appropriate medicines for nine out of 12 priority diseases in children were infrequently surveyed or not at all. A similar data deficit on age-appropriate medicines is detectable in the broader scientific literature. We also note that existing instruments for collecting data on the availability or prices of medicines are limited in their ability to generate the required data for children. We have identified four priorities as key for improved monitoring of access to medicines for children: (i) dedicated child medicine surveys are needed on availability and prices of child-appropriate medicines; (ii) standardized survey instruments should include age-appropriate medicines and dosages; (iii) health facility service readiness survey tools should include the collection of data on the price of child-appropriate medicines in addition to the availability of medicines; and (iv) sustainable development goal indicator 3.b.3 should be modified to enable the monitoring of access to medicines for children. These deficiencies need to be addressed to ensure the monitoring of access to child medicines as part of the sustainable development goal agenda for 2030 and to implement appropriate interventions for improving access for this vulnerable population. Disposer de medicaments adaptes aux enfants est essentiel a l'administration d'un traitement sur et efficace. Pourtant, nous avons observe de vastes lacunes dans les donnees requises pour evaluer l'acces a ces medicaments. Nous avons passe 50 enquetes au crible, a la recherche d'informations sur la disponibilite et le prix des medicaments pediatriques. Dans le cas de neufmaladies infantiles prioritaires sur douze, les medicaments adaptes aux enfants n'etaient pas ou peu etudies. Meme constat dans le contexte plus large de la litterature scientifique. Nous avons egalement remarque que les instruments servant a recolter des donnees sur la disponibilite ou le prix des medicaments avaient leurs limites et ne permettaient pas d'obtenir les informations requises concernant les enfants. Nous avons identifie quatre priorites majeures en vue d'ameliorer la surveillance de l'acces aux medicaments pediatriques: (i) la realisation d'enquetes sur les medicaments pediatriques afin d'en connaitre la disponibilite et le prix; (ii) l'integration des medicaments et dosages adequats dans les instruments d'enquete standard; (iii) outre la disponibilite, la prise en compte du prix des medicaments a usage pediatrique dans les outils d'evaluation de l'etat de preparation des services au sein des etablissements de sante; et enfin, (iv) la modification de l'indicateur 3.b.3 des objectifs de developpement durable, qui prevoirait des lors un controle de l'acces aux medicaments adaptes aux enfants. Ces lacunes doivent etre comblees pour assurer un suivi en matiere d'acces aux medicaments pediatriques dans le cadre du Programme de developpement durable a l'horizon 2030, mais aussi pour adopter les mesures correspondantes afin d'ameliorer la prise en charge de cette population vulnerable. Los medicamentos indicados para los ninos son esenciales para su tratamiento seguro y eficaz, pero se ha observado un gran vacio en los datos necesarios para supervisar de manera adecuada el acceso a estos medicamentos. Se han analizado los datos sobre la disponibilidad y el precio de los medicamentos indicados para los ninos en 50 encuestas. Estos medicamentos para nueve de las 12 enfermedades prioritarias infantiles se encuestaron con poca frecuencia o no se encuestaron en absoluto. En la literatura cientifica mas general, se detecta un deficit de datos similar sobre los medicamentos adecuados para la edad. Tambien se observa que los instrumentos existentes para recopilar los datos sobre la disponibilidad o los precios de los medicamentos son limitados en su capacidad para generar los datos necesarios en el caso de los ninos. Se han identificado cuatro prioridades para mejorar el seguimiento del acceso a los medicamentos pediatricos: (i) se necesitan encuestas especificas sobre la disponibilidad y los precios de los medicamentos indicados para los ninos; (ii) los instrumentos de encuesta estandarizados deben incluir medicamentos y dosis adecuados para la edad; (iii) las herramientas de encuesta sobre la disponibilidad de los servicios sanitarios deben incluir la recopilacion de los datos sobre el precio de los medicamentos indicados para los ninos, ademas de la disponibilidad de los medicamentos; y (iv) el indicador 3.b.3 del Objetivo de Desarrollo Sostenible se debe modificar para permitir el seguimiento del acceso a los medicamentos pediatricos. Es preciso solucionar estas deficiencias para garantizar el seguimiento del acceso a los medicamentos pediatricos como parte de la agenda de los objetivos de desarrollo sostenible para 2030 y aplicar las intervenciones adecuadas para mejorar el acceso de esta poblacion vulnerable., Introduction The importance of access to available and affordable essential medicines for all is embodied in targets 3.8 and 3.b of the sustainable development goals (SDGs) and remains a priority [...]

Published
2022
Full Text
View/download PDF

12. The impact of scheduling ketamine as an internationally controlled substance on anaesthesia care in Sub-Saharan Africa: a case study and key informant interviews

Author

Afd Pharmacoepi & Clinical Pharmacology, PECP - Centre for Pharmaceutical Policy and Regulation, Pharmacoepidemiology and Clinical Pharmacology, Ooms, Gaby I., Usman, Mohammed A., Reed, Tim, van den Ham, Hendrika A., Mantel-Teeuwisse, Aukje K., Afd Pharmacoepi & Clinical Pharmacology, PECP - Centre for Pharmaceutical Policy and Regulation, Pharmacoepidemiology and Clinical Pharmacology, Ooms, Gaby I., Usman, Mohammed A., Reed, Tim, van den Ham, Hendrika A., and Mantel-Teeuwisse, Aukje K.

Published
2024

13. Uptake of orphan drugs in the WHO essential medicines lists

Author

Afd Pharmacoepi & Clinical Pharmacology, PECP - Centre for Pharmaceutical Policy and Regulation, Pharmacoepidemiology and Clinical Pharmacology, Costa, Enrico, Moja, Lorenzo, Wirtz, Veronika J, van den Ham, Hendrika A, Huttner, Benedikt, Magrini, Nicola, Leufkens, Hubert Gm, Afd Pharmacoepi & Clinical Pharmacology, PECP - Centre for Pharmaceutical Policy and Regulation, Pharmacoepidemiology and Clinical Pharmacology, Costa, Enrico, Moja, Lorenzo, Wirtz, Veronika J, van den Ham, Hendrika A, Huttner, Benedikt, Magrini, Nicola, and Leufkens, Hubert Gm

Published
2024

14. Monitoring Access to Child Medicines: Introducing a Standardized Set of Age-Appropriate Medicines

Author

Afd Pharmacoepi & Clinical Pharmacology, PECP - Centre for Pharmaceutical Policy and Regulation, Pharmacoepidemiology and Clinical Pharmacology, Joosse, Iris R., Mantel-Teeuwisse, Aukje K., Suleman, Fatima, van den Ham, Hendrika A., Afd Pharmacoepi & Clinical Pharmacology, PECP - Centre for Pharmaceutical Policy and Regulation, Pharmacoepidemiology and Clinical Pharmacology, Joosse, Iris R., Mantel-Teeuwisse, Aukje K., Suleman, Fatima, and van den Ham, Hendrika A.

Published
2024

22. Safety of off‐label dose reduction of non‐vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

Author

van den Dries, Carline J., Pajouheshnia, Romin, van den Ham, Hendrika A., Souverein, Patrick, Moons, Karel G.M., Hoes, Arno W., Geersing, Geert Jan, van Doorn, Sander, Afd Pharmacoepi & Clinical Pharmacology, Sub Biomol.Mass Spectrometry & Proteom., Pharmacoepidemiology and Clinical Pharmacology, and Biomolecular Mass Spectrometry and Proteomics

Subjects
Pharmacology, Anticoagulation, non-vitamin K antagonist oral anticoagulants, Pharmacology (medical), Off-label dose reduction, Atrial fibrillation
Abstract

Aim: To investigate the effects of off-label non-vitamin K oral anticoagulant (NOAC) dose reduction compared with on-label standard dosing in atrial fibrillation (AF) patients in routine care. Methods: Population-based cohort study using data from the United Kingdom Clinical Practice Research Datalink, comparing adults with non-valvular AF receiving an off-label reduced NOAC dose to patients receiving an on-label standard dose. Outcomes were ischaemic stroke, major/non-major bleeding and mortality. Inverse probability of treatment weighting and inverse probability of censoring weighting on the propensity score were applied to adjust for confounding and informative censoring. Results: Off-label dose reduction occurred in 2466 patients (8.0%), compared with 18 108 (58.5%) on-label standard-dose users. Median age was 80 years (interquartile range [IQR] 73.0-86.0) versus 72 years (IQR 66-78), respectively. Incidence rates were higher in the off-label dose reduction group compared to the on-label standard dose group, for ischaemic stroke (0.94 vs 0.70 per 100 person years), major bleeding (1.48 vs 0.83), non-major bleeding (6.78 vs 6.16) and mortality (10.12 vs 3.72). Adjusted analyses resulted in a hazard ratio of 0.95 (95% confidence interval [CI] 0.57-1.60) for ischaemic stroke, 0.88 (95% CI 0.57-1.35) for major bleeding, 0.81 (95% CI 0.67-0.98) for non-major bleeding and 1.34 (95% CI 1.12-1.61) for mortality. Conclusion: In this large population-based study, the hazards for ischaemic stroke and major bleeding were low, and similar in AF patients receiving an off-label reduced NOAC dose compared with on-label standard dose users, while non-major bleeding risk appeared to be lower and mortality risk higher. Caution towards prescribing an off-label reduced NOAC dose is therefore required.

Published
2022

24. Traits, trends and hits of orphan drug designations in cystic fibrosis

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmaceutical Policy and Regulation, Costa, Enrico, Girotti, Silvia, van den Ham, Hendrika A., Cipolli, Marco, van der Ent, Cornelis K., Taylor-Cousar, Jennifer L., Leufkens, Hubert G.M., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmaceutical Policy and Regulation, Costa, Enrico, Girotti, Silvia, van den Ham, Hendrika A., Cipolli, Marco, van der Ent, Cornelis K., Taylor-Cousar, Jennifer L., and Leufkens, Hubert G.M.

Published
2023

25. Alignment in the registration, selection, procurement and reimbursement of essential medicines for childhood cancers in South Africa

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmaceutical Policy and Regulation, Joosse, Iris R., Van Den Ham, Hendrika A., Mantel-Teeuwisse, Aukje K., Suleman, Fatima, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmaceutical Policy and Regulation, Joosse, Iris R., Van Den Ham, Hendrika A., Mantel-Teeuwisse, Aukje K., and Suleman, Fatima

Published
2023

26. A systematic review of policies regulating or removing mark-ups in the pharmaceutical supply and distribution chain

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmaceutical Policy and Regulation, Joosse, Iris R., Tordrup, David, Glanville, Julie, Mantel-Teeuwisse, Aukje K., van den Ham, Hendrika A., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmaceutical Policy and Regulation, Joosse, Iris R., Tordrup, David, Glanville, Julie, Mantel-Teeuwisse, Aukje K., and van den Ham, Hendrika A.

Published
2023

27. Barriers to accessing internationally controlled essential medicines in sub-saharan Africa: A scoping review

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmaceutical Policy and Regulation, Ooms, Gaby I., van Oirschot, Janneke, de Kant, Denise, van den Ham, Hendrika A., Mantel-Teeuwisse, Aukje K., Reed, Tim, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmaceutical Policy and Regulation, Ooms, Gaby I., van Oirschot, Janneke, de Kant, Denise, van den Ham, Hendrika A., Mantel-Teeuwisse, Aukje K., and Reed, Tim

Published
2023

28. Improved knowledge on substandard and falsified (SF) medical products through a dedicated course for pharmacy students at three universities in sub-Saharan Africa

Author

Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, PECP - Centre for Pharmaceutical Policy and Regulation, Kusynová, Zuzana, Bais, Youssra, van den Ham, Hendrika A, Mantel-Teeuwisse, Aukje K, Etame-Loe, Gisele, Kaale, Eliangiringa, Sarr, Serigne Omar, Guiet-Mati, Fatima, Bourdillon-Esteve, Pernette, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, PECP - Centre for Pharmaceutical Policy and Regulation, Kusynová, Zuzana, Bais, Youssra, van den Ham, Hendrika A, Mantel-Teeuwisse, Aukje K, Etame-Loe, Gisele, Kaale, Eliangiringa, Sarr, Serigne Omar, Guiet-Mati, Fatima, and Bourdillon-Esteve, Pernette

Published
2023

29. Sustainable Development Goal indicator for measuring availability and affordability of medicines for children: a proof-of-concept study

Author

Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, PECP - Centre for Pharmaceutical Policy and Regulation, Joosse, Iris R, Mantel-Teeuwisse, Aukje K, Suleman, Fatima, van den Ham, Hendrika A, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, PECP - Centre for Pharmaceutical Policy and Regulation, Joosse, Iris R, Mantel-Teeuwisse, Aukje K, Suleman, Fatima, and van den Ham, Hendrika A

Published
2023

30. A critical review of methodologies used in pharmaceutical pricing policy analyses

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmaceutical Policy and Regulation, Joosse, Iris R, Tordrup, David, Bero, Lisa, Mantel-Teeuwisse, Aukje K, van den Ham, Hendrika A, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmaceutical Policy and Regulation, Joosse, Iris R, Tordrup, David, Bero, Lisa, Mantel-Teeuwisse, Aukje K, and van den Ham, Hendrika A

Published
2023

31. Evidence on the effectiveness of policies promoting price transparency -: A systematic review

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmaceutical Policy and Regulation, Joosse, Iris R., Tordrup, David, Glanville, Julie, Kotas, Eleanor, Mantel-Teeuwisse, Aukje K., van den Ham, Hendrika A., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmaceutical Policy and Regulation, Joosse, Iris R., Tordrup, David, Glanville, Julie, Kotas, Eleanor, Mantel-Teeuwisse, Aukje K., and van den Ham, Hendrika A.

Published
2023

32. Traits, trends and hits of orphan drug designations in cystic fibrosis

Author

Longziekten patientenzorg, Speerpunt Child Health, Child Health, Infection & Immunity, Costa, Enrico, Girotti, Silvia, van den Ham, Hendrika A., Cipolli, Marco, van der Ent, Cornelis K., Taylor-Cousar, Jennifer L., Leufkens, Hubert G.M., Longziekten patientenzorg, Speerpunt Child Health, Child Health, Infection & Immunity, Costa, Enrico, Girotti, Silvia, van den Ham, Hendrika A., Cipolli, Marco, van der Ent, Cornelis K., Taylor-Cousar, Jennifer L., and Leufkens, Hubert G.M.

Published
2023

33. Safety of off-label dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

Author

Circulatory Health, HAG Trombose, Epi Methoden, Cancer, JC onderzoeksprogramma Methodologie, Directie Raad van Bestuur, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, van den Dries, Carline J, Pajouheshnia, Romin, van den Ham, Hendrika A, Souverein, Patrick, Moons, Karel G M, Hoes, Arno W, Geersing, Geert-Jan, van Doorn, Sander, Circulatory Health, HAG Trombose, Epi Methoden, Cancer, JC onderzoeksprogramma Methodologie, Directie Raad van Bestuur, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, van den Dries, Carline J, Pajouheshnia, Romin, van den Ham, Hendrika A, Souverein, Patrick, Moons, Karel G M, Hoes, Arno W, Geersing, Geert-Jan, and van Doorn, Sander

Published
2023

35. Improved knowledge on substandard and falsified (SF) medical products through a dedicated course for pharmacy students at three universities in sub-Saharan Africa

Author

Kusynová, Zuzana, primary, Bais, Youssra, additional, van den Ham, Hendrika A, additional, Mantel-Teeuwisse, Aukje K, additional, Etame-Loe, Gisele, additional, Kaale, Eliangiringa, additional, Sarr, Serigne Omar, additional, Guiet-Mati, Fatima, additional, and Bourdillon-Esteve, Pernette, additional

Published
2023
Full Text
View/download PDF

36. Identifying the teaching content on substandard and falsified medical products in global pharmacy education as critical public health issue

Author

Kusynová, Zuzana, Kicken, Mart, van den Ham, Hendrika A., Mantel-Teeuwisse, Aukje K., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, and Pharmacoepidemiology and Clinical Pharmacology

Subjects
Response rate (survey), Medical education, Course materials, medicine.medical_specialty, Pharmacy education, business.industry, Public health, Pharmaceutical Science, Pharmacy, Pharmacy curriculum, Education, Substandard and falsified (SF) medical products, Taverne, medicine, Research article, business, Psychology, Curriculum
Abstract

Aim: To gain insight into the education about substandard and falsified (SF) medical products. Method: A digital survey was sent to 173 different schools of pharmacy around the world. Results: The response rate was 32% (55 responses, 37 countries). Most schools taught about SF medical products as a stand-alone course or as part of another course or module (67%), whereas 33% did not teach about the subject. The main focus of teaching was on detection (21%) and prevention (21%) of SF medical products, while reporting was taught the least (12%), indicating a knowledge gap in that area. A key barrier to introducing a new course that could close the gaps was insufficient time in pharmacy curriculum (n=33; 60%), while availability of ready-to-adopt course materials was considered as a helpful enabler. Conclusion: These insights can improve the understanding on what is already being taught on SF medical products, where the gaps are and inform the curriculum needed globally.

Published
2021

37. Missing data on accessibility of children's medicines

Author

Joosse, Iris R, Mantel-Teeuwisse, Aukje K, Wirtz, Veronika J, Suleman, Fatima, van den Ham, Hendrika A, Afd Pharmacoepi & Clinical Pharmacology, and Pharmacoepidemiology and Clinical Pharmacology

Subjects
Public Sector, Taverne, Costs and Cost Analysis, Humans, Private Sector, Drugs, Essential, Health Services Accessibility
Abstract

Child-appropriate medicines are essential for the safe and effective treatment of children, yet we have observed a large gap in the data required to adequately monitor access to these medicines. We have examined data on the availability and pricing of child-appropriate medicines across 50 surveys. Child-appropriate medicines for nine out of 12 priority diseases in children were infrequently surveyed or not at all. A similar data deficit on age-appropriate medicines is detectable in the broader scientific literature. We also note that existing instruments for collecting data on the availability or prices of medicines are limited in their ability to generate the required data for children. We have identified four priorities as key for improved monitoring of access to medicines for children: (i) dedicated child medicine surveys are needed on availability and prices of child-appropriate medicines; (ii) standardized survey instruments should include age-appropriate medicines and dosages; (iii) health facility service readiness survey tools should include the collection of data on the price of child-appropriate medicines in addition to the availability of medicines; and (iv) sustainable development goal indicator 3.b.3 should be modified to enable the monitoring of access to medicines for children. These deficiencies need to be addressed to ensure the monitoring of access to child medicines as part of the sustainable development goal agenda for 2030 and to implement appropriate interventions for improving access for this vulnerable population.

Published
2022

38. The Current State of Snakebite Care in Kenya, Uganda, and Zambia: Healthcare Workers’ Perspectives and Knowledge, and Health Facilities’ Treatment Capacity

Author

Ooms, Gaby I, van Oirschot, Janneke, Waldmann, Benjamin, von Bernus, Sophie, van den Ham, Hendrika A, Mantel-Teeuwisse, Aukje K, Reed, Tim, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, and Pharmacoepidemiology and Clinical Pharmacology

Subjects
Adult, Male, Health Knowledge, Attitudes, Practice, medicine.medical_specialty, Community education, Health Personnel, 030231 tropical medicine, MEDLINE, Psychological intervention, Snake Bites, Zambia, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Health facility, Surveys and Questionnaires, Virology, Environmental health, Intervention (counseling), Taverne, Health care, medicine, Humans, Uganda, Facilities treatment, Antivenins, business.industry, Public health, Articles, Kenya, Cross-Sectional Studies, Infectious Diseases, Female, Parasitology, Health Facilities, business
Abstract

Snakebites continue to be a public health concern in sub-Saharan Africa, where availability of appropriate medical treatment is rare, even though death and disability can be prevented with timely intervention. A challenge is the lack of sociopolitical studies to inform health policies. This study aimed to identify snakebite patient profiles, healthcare workers’ (HCWs) knowledge of snakebite, and facilities’ snakebite treatment capacity in Kenya, Uganda, and Zambia to inform interventions to improve access to appropriate treatment. The research comprised a cross-sectional key informant survey among HCWs from health facilities in Kenya (n = 145), Uganda (n = 144), and Zambia (n = 108). Data were collected between March 2018 and November 2019. Most of the HCWs suggested that the number of snakebite incidents was similar between the genders, that most patients were aged 21–30 years, and most people were bitten when farming or walking. Overall, only 12% of HCWs had received formal training in snakebite management. Only about 20% of HCWs in each country said their health facility had the medicines needed to treat snakebites, with antivenom available in 0–34% of facilities across the sectors and countries, and snakebites were not systematically recorded. This research shows that an integrative approach through policies to increase resource allocation for health system strengthening, including community education, HCW training, and improved access to snakebite treatment, is needed. Part of this approach should include regulations that ensure antivenoms available in health facilities meet quality control standards and that snakebites are accommodated into routine reporting systems to assess progress.

Published
2021

39. A comparative human rights analysis of laws and policies for adolescent contraception in Uganda and Kenya

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Perehudoff, Katrina, Kibira, Denis, Wuyts, Elke, Pericas, Carles, Omwoha, Joyce, van den Ham, Hendrika A., Mantel-Teeuwisse, Aukje K., Michielsen, Kristien, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Perehudoff, Katrina, Kibira, Denis, Wuyts, Elke, Pericas, Carles, Omwoha, Joyce, van den Ham, Hendrika A., Mantel-Teeuwisse, Aukje K., and Michielsen, Kristien

Published
2022

40. Healthcare workers’ perspectives on access to sexual and reproductive health services in the public, private and private not-for-profit sectors: insights from Kenya, Tanzania, Uganda and Zambia

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Ooms, Gaby I., van Oirschot, Janneke, Okemo, Dorothy, Reed, Tim, van den Ham, Hendrika A., Mantel-Teeuwisse, Aukje K., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Ooms, Gaby I., van Oirschot, Janneke, Okemo, Dorothy, Reed, Tim, van den Ham, Hendrika A., and Mantel-Teeuwisse, Aukje K.

Published
2022

41. Safety of off-label dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

Author

Afd Pharmacoepi & Clinical Pharmacology, Sub Biomol.Mass Spectrometry & Proteom., Pharmacoepidemiology and Clinical Pharmacology, Biomolecular Mass Spectrometry and Proteomics, van den Dries, Carline J., Pajouheshnia, Romin, van den Ham, Hendrika A., Souverein, Patrick, Moons, Karel G.M., Hoes, Arno W., Geersing, Geert Jan, van Doorn, Sander, Afd Pharmacoepi & Clinical Pharmacology, Sub Biomol.Mass Spectrometry & Proteom., Pharmacoepidemiology and Clinical Pharmacology, Biomolecular Mass Spectrometry and Proteomics, van den Dries, Carline J., Pajouheshnia, Romin, van den Ham, Hendrika A., Souverein, Patrick, Moons, Karel G.M., Hoes, Arno W., Geersing, Geert Jan, and van Doorn, Sander

Published
2022

42. Missing data on accessibility of children's medicines

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Joosse, Iris R, Mantel-Teeuwisse, Aukje K, Wirtz, Veronika J, Suleman, Fatima, van den Ham, Hendrika A, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Joosse, Iris R, Mantel-Teeuwisse, Aukje K, Wirtz, Veronika J, Suleman, Fatima, and van den Ham, Hendrika A

Published
2022

43. Longitudinal study of Good Pharmacy Practice roles covered at the annual world pharmacy congresses 2003–2019

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Kusynová, Zuzana, van den Ham, Hendrika A., Leufkens, Hubert G.M., Mantel-Teeuwisse, Aukje K., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Kusynová, Zuzana, van den Ham, Hendrika A., Leufkens, Hubert G.M., and Mantel-Teeuwisse, Aukje K.

Published
2022

44. Additional file 3 of Healthcare workers’ perspectives on access to sexual and reproductive health services in the public, private and private not-for-profit sectors: insights from Kenya, Tanzania, Uganda and Zambia

Author

Ooms, Gaby I., van Oirschot, Janneke, Okemo, Dorothy, Reed, Tim, van den Ham, Hendrika A., and Mantel-Teeuwisse, Aukje K.

Abstract

Additional file 3. HCWs perspectives on access to SRH barriers and recommendations for improvement, per country. Numbers represent percentage of HCWs that mentioned this barrier or recommendation.

Published
2022
Full Text
View/download PDF

45. Additional file 1 of A comparative human rights analysis of laws and policies for adolescent contraception in Uganda and Kenya

Author

Perehudoff, Katrina, Kibira, Denis, Wuyts, Elke, Pericas, Carles, Omwoha, Joyce, van den Ham, Hendrika A., Mantel-Teeuwisse, Aukje K., and Michielsen, Kristien

Subjects
parasitic diseases
Abstract

Additional file 1. List of documents screened for inclusion in the article ���A comparative human rights analysis of laws and policies for adolescent contraception in Uganda and Kenya���.

Published
2022
Full Text
View/download PDF

46. Additional file 2 of Healthcare workers’ perspectives on access to sexual and reproductive health services in the public, private and private not-for-profit sectors: insights from Kenya, Tanzania, Uganda and Zambia

Author

Ooms, Gaby I., van Oirschot, Janneke, Okemo, Dorothy, Reed, Tim, van den Ham, Hendrika A., and Mantel-Teeuwisse, Aukje K.

Abstract

Additional file 2. HCWs perspectives on access to SRH barriers and recommendations for improvement, per sector. Crude and adjusted models.

Published
2022
Full Text
View/download PDF

48. Safety of off‐label dose reduction of non‐vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.

Author

van den Dries, Carline J., Pajouheshnia, Romin, van den Ham, Hendrika A., Souverein, Patrick, Moons, Karel G. M., Hoes, Arno W., Geersing, Geert‐Jan, and van Doorn, Sander

Subjects
APIXABAN, ATRIAL fibrillation, ORAL medication, ISCHEMIC stroke, MEDICAL research, CONFIDENCE intervals
Abstract

Aim: To investigate the effects of off‐label non‐vitamin K oral anticoagulant (NOAC) dose reduction compared with on‐label standard dosing in atrial fibrillation (AF) patients in routine care. Methods: Population‐based cohort study using data from the United Kingdom Clinical Practice Research Datalink, comparing adults with non‐valvular AF receiving an off‐label reduced NOAC dose to patients receiving an on‐label standard dose. Outcomes were ischaemic stroke, major/non‐major bleeding and mortality. Inverse probability of treatment weighting and inverse probability of censoring weighting on the propensity score were applied to adjust for confounding and informative censoring. Results: Off‐label dose reduction occurred in 2466 patients (8.0%), compared with 18 108 (58.5%) on‐label standard‐dose users. Median age was 80 years (interquartile range [IQR] 73.0‐86.0) versus 72 years (IQR 66‐78), respectively. Incidence rates were higher in the off‐label dose reduction group compared to the on‐label standard dose group, for ischaemic stroke (0.94 vs 0.70 per 100 person years), major bleeding (1.48 vs 0.83), non‐major bleeding (6.78 vs 6.16) and mortality (10.12 vs 3.72). Adjusted analyses resulted in a hazard ratio of 0.95 (95% confidence interval [CI] 0.57‐1.60) for ischaemic stroke, 0.88 (95% CI 0.57‐1.35) for major bleeding, 0.81 (95% CI 0.67‐0.98) for non‐major bleeding and 1.34 (95% CI 1.12‐1.61) for mortality. Conclusion: In this large population‐based study, the hazards for ischaemic stroke and major bleeding were low, and similar in AF patients receiving an off‐label reduced NOAC dose compared with on‐label standard dose users, while non‐major bleeding risk appeared to be lower and mortality risk higher. Caution towards prescribing an off‐label reduced NOAC dose is therefore required. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

50. Donor Commitments and Disbursements for Sexual and Reproductive Health Aid in Kenya, Tanzania, Uganda and Zambia

Author

Kibira, Denis, Asiimwe, Cornelia, Muwonge, Moses, van den Ham, Hendrika A., Reed, Tim, Leufkens, Hubert G., Mantel-Teeuwisse, Aukje K., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, and Pharmacoepidemiology and Clinical Pharmacology

Subjects
official development aid, Sexual and reproductive health and rights, Population, Zambia, Kenya/epidemiology, Tanzania, 03 medical and health sciences, 0302 clinical medicine, Health facility, Africa, Northern, Pregnancy, 0502 economics and business, Global health, Humans, Northern, Uganda, 030212 general & internal medicine, 050207 economics, Socioeconomics, education, Reproductive health, Original Research, education.field_of_study, biology, business.industry, sexual and reproductive health and rights, Mortality rate, Environmental and Occupational Health, 05 social sciences, donor aid, low-and-middle-income countries, Infant, Newborn, Public Health, Environmental and Occupational Health, Infant, Newborn, biology.organism_classification, Tanzania/epidemiology, Kenya, Infant mortality, Reproductive Health, Africa, Female, Business, Public Health, Public aspects of medicine, RA1-1270, development assistance for health, Zambia/epidemiology
Abstract

Background: Sexual and Reproductive Health and Rights (SRHR) investments are critical to people's well-being. However, despite the demonstrated returns on investments, underfunding of SRHR still persists. The objective of this study was to characterize donor commitments and disbursements to SRH aid in four sub-Saharan countries of Kenya, Tanzania, Uganda and Zambia and to compare trends in donor aids with SRH outcome and impact indicators for each of these countries.Methods: The study is a secondary analysis of data from the Organization for Economic Co-operation and Development's Assistance creditor reporting system and SRH indicator data from the Global Health Observatory and country demographic health surveys for a 16-year period (2002–2017). We downloaded and compared commitments to disbursements of all donors for population policies, programs and reproductive health for the four African countries. SRH indicators were stratified into health facility level process/outcome indicators (modern contraceptive prevalence rate, unmet need for family planning, antenatal care coverage and skilled birth attendance) and health impact level indicators (maternal mortality ratio, newborn mortality rate, infant mortality rate and under five mortality rate).Results: Donor commitments for SRH aid grew on average by 20% while disbursements grew by 21% annually between 2002 and 2017. The overall disbursement rate was 93%. Development Assistance Cooperation (DAC) countries donated the largest proportion (79%) of aid. Kenya took 33% of total aid, followed by Tanzania 26%, Uganda 23% and then Zambia (18%). There was improvement in all SRH outcome and impact indicators, but not enough to meet targets.Conclusion: Donor aid to SRH grew over time and in the same period indicators improved, but improvement remained slow. Unpredictability and insufficiency of aid may be disruptive to recipient country planning. Donors and low- and middle-income countries should increase funding in order to meet global SRHR targets.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results